Current methods of image interpretation are limited and cannot comprehend the vast amounts of data and images. Altis’s promising technology, applying deep learning to imaging has the potential to significantly reduce time and costs of clinical trials while also predicting patient outcomes more accurately. Extracting new imaging digital biomarkers from longitudinal images can help Debiopharm accelerate time to market and improve success rates of our trials. The company is also exploring digital twins which we could leverage using virtual control arms.